CY1123024T1 - Συνθεσεις για χρηση σε μεθοδους για τη θεραπεια πληγων, διαταραχων, και ασθενειων του δερματος - Google Patents
Συνθεσεις για χρηση σε μεθοδους για τη θεραπεια πληγων, διαταραχων, και ασθενειων του δερματοςInfo
- Publication number
- CY1123024T1 CY1123024T1 CY20201100503T CY201100503T CY1123024T1 CY 1123024 T1 CY1123024 T1 CY 1123024T1 CY 20201100503 T CY20201100503 T CY 20201100503T CY 201100503 T CY201100503 T CY 201100503T CY 1123024 T1 CY1123024 T1 CY 1123024T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- subject
- skin
- compositions
- disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 2
- 206010052428 Wound Diseases 0.000 title 1
- 208000027418 Wounds and injury Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000017520 skin disease Diseases 0.000 abstract 2
- 102000004510 Collagen Type VII Human genes 0.000 abstract 1
- 108010017377 Collagen Type VII Proteins 0.000 abstract 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 abstract 1
- 102000011782 Keratins Human genes 0.000 abstract 1
- 108010076876 Keratins Proteins 0.000 abstract 1
- 102100035199 Procollagen glycosyltransferase Human genes 0.000 abstract 1
- 101710102040 Procollagen glycosyltransferase Proteins 0.000 abstract 1
- 206010072170 Skin wound Diseases 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 230000003436 cytoskeletal effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000001965 increasing effect Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1748—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
- C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Η παρούσα αποκάλυψη αφορά, εν μέρει, σε φαρμακευτικές συνθέσεις που περιλαμβάνουν ένα ή περισσότερα πολυνουκλεοτίδια κατάλληλα για ενίσχυση, αύξηση, επαύξηση ή/και συμπλήρωση των επιπέδων Κολλαγόνου άλφα-1 (VII) αλύσου πολυπεπτιδίου ή/και Λυσύλ υδροξυλάσης 3 πολυπεπτιδίου ή/και Κεράτινης τύπου Ι κυτοσκελετικό 17 πολυπεπτιδίου σε ένα υποκείμενο. Η παρούσα αποκάλυψη επίσης αφορά, εν μέρει, σε φαρμακευτικές συνθέσεις και μεθόδους χρήσης για παροχή προφυλακτικής, ανακουφιστικής ή θεραπευτικής ανακούφισης πληγής, διαταραχής ή ασθένειας του δέρματος σε ένα υποκείμενο, που συμπεριλαμβάνει υποκείμενο που έχει, ή είναι σε κίνδυνο να αναπτύσσει, ένα ή περισσότερα συμπτώματα πομφολυγώδους επιδερμόλυσης.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662320316P | 2016-04-08 | 2016-04-08 | |
| PCT/US2016/068974 WO2017176336A1 (en) | 2016-04-08 | 2016-12-28 | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123024T1 true CY1123024T1 (el) | 2021-10-29 |
Family
ID=57822104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100503T CY1123024T1 (el) | 2016-04-08 | 2020-06-05 | Συνθεσεις για χρηση σε μεθοδους για τη θεραπεια πληγων, διαταραχων, και ασθενειων του δερματος |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US9877990B2 (el) |
| EP (2) | EP3377637B1 (el) |
| JP (3) | JP6970086B2 (el) |
| KR (1) | KR20180128016A (el) |
| CN (1) | CN109072255A (el) |
| AU (3) | AU2016401692B2 (el) |
| CA (1) | CA3017487A1 (el) |
| CL (3) | CL2018002814A1 (el) |
| CY (1) | CY1123024T1 (el) |
| DK (1) | DK3377637T3 (el) |
| ES (1) | ES2796488T3 (el) |
| HR (1) | HRP20200853T1 (el) |
| HU (1) | HUE049237T2 (el) |
| LT (1) | LT3377637T (el) |
| MX (2) | MX2018012135A (el) |
| PL (1) | PL3377637T3 (el) |
| PT (1) | PT3377637T (el) |
| RS (1) | RS60410B1 (el) |
| SG (1) | SG11201808314QA (el) |
| SI (1) | SI3377637T1 (el) |
| WO (1) | WO2017176336A1 (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017013858A2 (pt) | 2014-12-26 | 2018-02-27 | Univ Emory | n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos |
| JP6970086B2 (ja) | 2016-04-08 | 2021-11-24 | クリスタル バイオテック，インコーポレイティド | 皮膚の創傷、障害、及び疾患を処置するための組成物及び方法 |
| CN110312506A (zh) * | 2016-11-14 | 2019-10-08 | 密歇根大学董事会 | 用于阻挡紫外线辐射的组合物和方法 |
| CA3049652A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| MX2020005392A (es) | 2017-12-07 | 2020-12-07 | Univ Emory | N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos. |
| CA3094345A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| WO2019210219A1 (en) | 2018-04-27 | 2019-10-31 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
| CA3112627A1 (en) | 2018-09-24 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
| CA3112633A1 (en) | 2018-09-26 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of skin diseases |
| WO2020149395A1 (ja) * | 2019-01-18 | 2020-07-23 | 国立大学法人大阪大学 | 栄養障害型表皮水疱症治療薬 |
| US10829529B2 (en) | 2019-02-08 | 2020-11-10 | Krystal Biotech, Inc. | Compositions and methods for delivering CFTR polypeptides |
| EP3946596A4 (en) * | 2019-03-27 | 2022-12-21 | Phoenix Tissue Repair, Inc. | SYSTEMS AND METHODS OF PRODUCING COLLAGEN COMPOSITIONS 7 |
| EP4025699A1 (en) | 2019-09-03 | 2022-07-13 | Krystal Biotech, Inc. | Compositions and methods for the treatment of congenital ichthyoses |
| CN112724225B (zh) * | 2019-10-28 | 2023-09-26 | 中国医学科学院药物研究所 | 一种角蛋白bd-6、制法和其药物组合物与用途 |
| EP4077688A1 (en) | 2019-12-20 | 2022-10-26 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
| CN117412986A (zh) | 2021-04-02 | 2024-01-16 | 克里斯托生物技术股份有限公司 | 用于癌症疗法的病毒载体 |
| WO2023064806A1 (en) | 2021-10-12 | 2023-04-20 | Phoenix Tissue Repair, Inc. | Collagen 7 protein replacement therapy |
| CN117143223B (zh) * | 2022-08-23 | 2024-03-08 | 山西锦波生物医药股份有限公司 | 一种生物合成人体结构性材料的制备方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672344A (en) * | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
| IL132087A0 (en) * | 1997-04-10 | 2001-03-19 | Univ Southern California | Modified proteins which bind extracellular matrix components |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| GB9715085D0 (en) * | 1997-07-18 | 1997-09-24 | Jahoda Amanda J | Gene therapy vehicle |
| US6106826A (en) * | 1997-12-17 | 2000-08-22 | Wisconsin Alumni Research Foundation | Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy |
| GB9801930D0 (en) * | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| WO1999064094A1 (en) * | 1998-06-12 | 1999-12-16 | Aradigm Corporation | Methods of delivering aerosolized polynucleotides to the respiratory tract |
| JP2003535565A (ja) | 1998-12-31 | 2003-12-02 | アーチ ディベロプメント コーポレイション | 新生物疾患の治療に有用な組換え単純ヘルペスウイルス |
| GB9930418D0 (en) * | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| AU1788502A (en) * | 2000-11-28 | 2002-06-11 | Univ Chicago | Genetically engineered herpes virus for the treatment of cardiovascular disease |
| AU2003298786A1 (en) | 2002-11-26 | 2004-06-18 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| CN101203530A (zh) * | 2004-10-28 | 2008-06-18 | 匹兹堡大学高等教育联邦体系 | 关于脊髓损伤疼痛的外周递送的谷氨酸脱羧酶基因治疗 |
| RU2007131689A (ru) * | 2005-01-21 | 2009-02-27 | Интроджен Тетрапьютикс, Инк. (Us) | Местное введение терапевтических и профилактических нуклеиновых кислот, обеспечивающее их пролонгированное действие на клетки-мишени |
| AU2006252406B2 (en) * | 2005-06-01 | 2012-05-17 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| US8703703B2 (en) * | 2006-12-20 | 2014-04-22 | University Of Central Flordia Research Foundation, Inc. | MCPIP as wound therapy |
| WO2008106646A2 (en) * | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
| US20080289058A1 (en) * | 2007-05-14 | 2008-11-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
| WO2009105690A2 (en) * | 2008-02-21 | 2009-08-27 | Targeted Genetics Corporation | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| CN102212559B (zh) | 2011-04-14 | 2014-04-09 | 郑州威瑞生物技术有限公司 | 一种重组的hsv扩增子载体及其用途 |
| US9340783B2 (en) * | 2011-10-11 | 2016-05-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Exon skipping therapy for dystrophic epidermolysis bullosa |
| GB201202561D0 (en) | 2012-02-15 | 2012-03-28 | Univ Dundee | Treatment of skin disorders |
| CN104768567B (zh) * | 2012-05-18 | 2017-07-11 | 奥塔哥创业有限公司 | 用于伤口愈合的联合治疗和组合物 |
| AU2014223243B2 (en) * | 2013-03-01 | 2019-10-17 | Regents Of The University Of Minnesota | Talen-based gene correction |
| BR112015022868B1 (pt) * | 2013-03-14 | 2023-05-16 | Ethris Gmbh | Composições de mrna de cftr e usos e métodos relacionados |
| WO2015009952A1 (en) * | 2013-07-17 | 2015-01-22 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production |
| ES2810800T3 (es) * | 2013-10-28 | 2021-03-09 | Univ Pittsburgh Commonwealth Sys Higher Education | Vector de HSV oncolítico |
| MX2016009771A (es) | 2014-01-31 | 2016-11-14 | Factor Bioscience Inc | Metodos y productos para la produccion y administracion de acido nucleico. |
| GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
| WO2016049183A1 (en) * | 2014-09-24 | 2016-03-31 | Aerpio Therapeutics, Inc. | Ve-ptp extracellular domain antibodies delivered by a gene therapy vector |
| JP6925805B2 (ja) * | 2014-10-31 | 2021-08-25 | 京都府公立大学法人 | ラミニンによる角膜の新規治療 |
| US20180148711A1 (en) * | 2015-05-28 | 2018-05-31 | Coda Biotherapeutics, Inc. | Genome editing vectors |
| CN109069668B (zh) * | 2015-12-14 | 2023-04-18 | 宾夕法尼亚州大学信托人 | 用于眼病的基因疗法 |
| EP3432905B1 (en) * | 2016-03-25 | 2022-06-01 | PeriphaGen, Inc. | Hsv vectors for delivery of nt3 and treatment of cipn |
| DK3432912T3 (da) * | 2016-03-25 | 2023-03-13 | Periphagen Inc | Hsv-vektorer med høj transduktion |
| JP6970086B2 (ja) | 2016-04-08 | 2021-11-24 | クリスタル バイオテック，インコーポレイティド | 皮膚の創傷、障害、及び疾患を処置するための組成物及び方法 |
| CA3094345A1 (en) | 2018-04-12 | 2019-10-17 | Krystal Biotech, Inc. | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| WO2019210219A1 (en) | 2018-04-27 | 2019-10-31 | Krystal Biotech, Inc. | Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications |
| JP2021529531A (ja) | 2018-06-29 | 2021-11-04 | クリスタル バイオテック インコーポレイテッド | 抗体送達のための組成物及び方法 |
-
2016
- 2016-12-28 JP JP2018521309A patent/JP6970086B2/ja active Active
- 2016-12-28 CA CA3017487A patent/CA3017487A1/en active Pending
- 2016-12-28 PT PT168268738T patent/PT3377637T/pt unknown
- 2016-12-28 DK DK16826873.8T patent/DK3377637T3/da active
- 2016-12-28 EP EP16826873.8A patent/EP3377637B1/en active Active
- 2016-12-28 LT LTEP16826873.8T patent/LT3377637T/lt unknown
- 2016-12-28 CN CN201680084419.7A patent/CN109072255A/zh active Pending
- 2016-12-28 RS RS20200669A patent/RS60410B1/sr unknown
- 2016-12-28 PL PL16826873T patent/PL3377637T3/pl unknown
- 2016-12-28 KR KR1020187030112A patent/KR20180128016A/ko not_active Application Discontinuation
- 2016-12-28 US US15/393,151 patent/US9877990B2/en active Active
- 2016-12-28 MX MX2018012135A patent/MX2018012135A/es unknown
- 2016-12-28 EP EP20161137.3A patent/EP3712273A1/en active Pending
- 2016-12-28 WO PCT/US2016/068974 patent/WO2017176336A1/en active Application Filing
- 2016-12-28 HU HUE16826873A patent/HUE049237T2/hu unknown
- 2016-12-28 AU AU2016401692A patent/AU2016401692B2/en active Active
- 2016-12-28 SG SG11201808314QA patent/SG11201808314QA/en unknown
- 2016-12-28 SI SI201630776T patent/SI3377637T1/sl unknown
- 2016-12-28 ES ES16826873T patent/ES2796488T3/es active Active
-
2017
- 2017-12-21 US US15/851,488 patent/US10155016B2/en active Active
-
2018
- 2018-10-03 CL CL2018002814A patent/CL2018002814A1/es unknown
- 2018-10-04 MX MX2022006072A patent/MX2022006072A/es unknown
- 2018-10-31 US US16/177,153 patent/US10441614B2/en active Active
-
2019
- 2019-10-10 US US16/598,982 patent/US11185564B2/en active Active
- 2019-12-13 AU AU2019280069A patent/AU2019280069B2/en active Active
-
2020
- 2020-05-27 HR HRP20200853TT patent/HRP20200853T1/hr unknown
- 2020-06-05 CY CY20201100503T patent/CY1123024T1/el unknown
-
2021
- 2021-04-09 CL CL2021000881A patent/CL2021000881A1/es unknown
- 2021-10-27 JP JP2021175260A patent/JP7480105B2/ja active Active
- 2021-11-17 US US17/529,161 patent/US20220273737A1/en not_active Abandoned
-
2022
- 2022-06-30 AU AU2022204729A patent/AU2022204729A1/en active Pending
- 2022-11-30 US US18/060,515 patent/US11865148B2/en active Active
-
2023
- 2023-03-15 CL CL2023000743A patent/CL2023000743A1/es unknown
- 2023-06-27 US US18/342,284 patent/US20230414686A1/en active Pending
- 2023-07-04 JP JP2023109819A patent/JP2023118838A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123024T1 (el) | Συνθεσεις για χρηση σε μεθοδους για τη θεραπεια πληγων, διαταραχων, και ασθενειων του δερματος | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
| CY1124778T1 (el) | Αντισωματα anti-asic1 και χρησεις αυτων | |
| UY38263A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| BR112019000005A2 (pt) | inibidores de pde9 para o tratamento de doenças periféricas | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| CL2017002825A1 (es) | Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2 | |
| EA201891913A1 (ru) | Улучшенные препараты клеток-предшественников взрослой печени | |
| EA202091995A1 (ru) | Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека | |
| CY1125101T1 (el) | Συνθεσεις και μεθοδοι διεγερσης βλαστοκυτταρων | |
| CY1122892T1 (el) | Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
| BR112016028895A2 (pt) | composições biofotônicas termofixas e usos destas | |
| CY1122882T1 (el) | Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
| CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
| CY1126031T1 (el) | Συνθεσεις για καθαρισμο του παχεος εντερου και την αντιμετωπιση γαστρεντερικων διαταραχων | |
| CO2019003865A2 (es) | Proteína terapéutica | |
| CY1124162T1 (el) | Ενας συνδυασμος κυνουρενινης και αντιγονοπαρουσιαστικων κυτταρων (απκ) ως θεραπευτικες ουσιες και μεθοδοι για τη χρηση τους στην ανοσορυθμιση | |
| MX2018013860A (es) | Composiciones cosmeticas para reparacion cutanea. | |
| BR112021017550A2 (pt) | Métodos de tratamento da amiloidose al | |
| BR112015024221A2 (pt) | exopolissacarídeo, uso do exopolissacarídeio, e, composição cosmética ou dermofarmacêutica | |
| CY1126054T1 (el) | Πεπτιδια για θεραπεια και αποτροπη διαβητη και συναφων διαταραχων | |
| CY1124964T1 (el) | Τοπικη συνθεση για την θεραπευτικη αντιμετωπιση δερματικων διαταραχων συμπεριλαμβανομενης της ανδρικης τριχοπτωσης |